皮肤鳞状细胞癌表观遗传学发病机制

国际肿瘤学杂志››2020,Vol. 47››Issue (9): 569-572.doi:10.3760/cma.j.cn371439-20200123-00080

皮肤鳞状细胞癌表观遗传学发病机制

桑莹冰¹, 梁俊琴²()

¹新疆医科大学研究生学院,乌鲁木齐 830054
²新疆维吾尔自治区人民医院皮肤科,乌鲁木齐 830000

收稿日期:2020-01-23修回日期:2020-05-13出版日期:2020-09-08发布日期:2020-10-27
通讯作者:梁俊琴 E-mail:zyeemail@163.com
基金资助:
国家自然科学基金(81760494)

Epigenetic pathogenesis of cutaneous squamous cell carcinoma

Sang Yingbing¹, Liang Junqin²()

¹Department of Postgraduate, Xinjiang Medical University, Urumqi 830054, China
²Department of Dermatology, People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi 830000, China

Received:2020-01-23Revised:2020-05-13Online:2020-09-08Published:2020-10-27
Contact:Liang Junqin E-mail:zyeemail@163.com
Supported by:
National Natural Science Foundation of China(81760494)

摘要/Abstract

摘要：

皮肤鳞状细胞癌(CSCC)是起源于表皮及其附属器角质形成细胞的一种恶性肿瘤,病因及发病机制复杂且尚不明确。CSCC的发病率在全球范围内总体上呈增长趋势,使得对其发病机制的研究日渐增多。表观遗传不改变基因组序列,通过DNA甲基化、组蛋白修饰、非编码RNA、染色质重塑等方式调控基因表达。其可逆、稳定的遗传特征将为CSCC发病机制研究提供新的思路。

关键词:皮肤肿瘤,肿瘤,鳞状细胞,DNA甲基化,组蛋白密码,非编码RNA

Abstract:

Cutaneous squamous cell carcinoma (CSCC) is a kind of malignant tumor originated from keratinocytes within the epidermis and its appendages. Its etiology and pathogenesis are complex and unclear. The incidence of CSCC is increasing in the whole world, which makes the research on its pathogenesis increasing day by day. Epigenetics does not change genome sequence, but regulates gene expression by DNA methylation, histone modification, noncoding RNA, chromatin remodeling and so on. Its reversible and stable genetic characteristics will provide a new idea for the study of pathogenesis of CSCC.

Key words:Skin neoplasms,Neoplasms, squamous cell,DNA methylation,Histone code,Non-coding RNA

桑莹冰, 梁俊琴. 皮肤鳞状细胞癌表观遗传学发病机制[J]. 国际肿瘤学杂志, 2020, 47(9): 569-572.

Sang Yingbing, Liang Junqin. Epigenetic pathogenesis of cutaneous squamous cell carcinoma[J]. Journal of International Oncology, 2020, 47(9): 569-572.

参考文献22

[1]	Venables ZC, Nijsten T, Wong KF, et al. Epidemiology of basal and cutaneous squamous cell carcinoma in the U.K.2013-15: a cohort study[J]. Br J Dermatol, 2019,181(3):474-482. DOI: 10.1111/bjd.17873. doi:10.1111/bjd.17873pmid:30864158
[2]	Stang A, Khil L, Kajüter H, et al. Incidence and mortality for cutaneous squamous cell carcinoma: comparison across three continents[J]. J Eur Acad Dermatol Venereol, 2019,33 Suppl 8: 6-10. DOI: 10.1111/jdv.15967. doi:10.1111/jdv.15318pmid:30811690
[3]	Umezono Y, Sato Y, Noto M, et al. Incidence rate of cutaneous squamous cell carcinoma is rapidly increasing in Akita Prefecture: urgent alert for super-aged society[J]. J Dermatol, 2019,46(3):259-262. DOI: 10.1111/1346-8138.14759. doi:10.1111/1346-8138.14759pmid:30614560
[4]	Hillen U, Leiter U, Haase S, et al. Advanced cutaneous squamous cell carcinoma: a retrospective analysis of patient profiles and treatment patterns—results of a non-interventional study of the DeCOG[J]. Eur J Cancer, 2018,96:34-43. DOI: 10.1016/j.ejca.2018.01.075. doi:10.1016/j.ejca.2018.01.075pmid:29665511
[5]	Ando M, Saito Y, Xu G, et al. Chromatin dysregulation and DNA methylation at transcription start sites associated with transcriptional repression in cancers[J]. Nat Commun, 2019,10(1):2415. DOI: 10.1038/s41467-019-09937-w. doi:10.1038/s41467-019-10557-7pmid:31142745
[6]	Li J, Hu WX, Luo SQ, et al. Promoter methylation induced epigene-tic silencing of DAZAP2, a downstream effector of p38/MAPK pathway, in multiple myeloma cells[J]. Cell Signal, 2019,60:136-145. DOI: 10.1016/j.cellsig.2019.04.012. doi:10.1016/j.cellsig.2019.04.012pmid:31034872
[7]	Hervás-Marín D, Higgins F, Sanmartín O, et al. Genome wide DNA methylation profiling identifies specific epigenetic features in high-risk cutaneous squamous cell carcinoma[J]. PLoS One, 2019,14(12):e0223341. DOI: 10.1371/journal.pone.0223341. doi:10.1371/journal.pone.0223341pmid:31860637
[8]	Yang Y, Wu R, Sargsyan D, et al. UVB drives different stages of epigenome alterations during progression of skin cancer[J]. Cancer Lett, 2019,449:20-30. DOI: 10.1016/j.canlet.2019.02.010. doi:10.1016/j.canlet.2019.02.010pmid:30771437
[9]	Tam S, Yao CMK, Amit M, et al. Association of immunosuppression with outcomes of patients with cutaneous squamous cell carcinoma of the head and neck[J]. JAMA Otolaryngol Head Neck Surg, 2019,146(2):128-135. DOI: 10.1001/jamaoto.2019.3751. doi:10.1001/jamaoto.2019.3751pmid:31804658
[10]	Jambusaria-Pahlajani A, Crow LD, Lowenstein S, et al. Predicting skin cancer in organ transplant recipients: development of the SUNTRAC screening tool using data from a multicenter cohort study[J]. Transpl Int, 2019,12:1259-1267. DOI: 10.1111/tri.13493.
[11]	Peters FS, Peeters AMA, Mandaviya PR, et al. Differentially methy-lated regions in T cells identify kidney transplant patients at risk for de novo skin cancer[J]. Clin Epigenetics, 2018,10:81. DOI: 10.1186/s13148-018-0519-7. doi:10.1186/s13148-018-0519-7pmid:29946375
[12]	Peters FS, Peeters AMA, van den Bosch TPP, et al. Disrupted regulation of serpinB9 in circulating T cells is associated with an increased risk for post-transplant skin cancer[J]. Clin Exp Immunol, 2019,197(3):341-351. DOI: 10.1111/cei.13309. doi:10.1111/cei.13309pmid:31059128
[13]	Gao X, Cheng Z, Yuan H, et al. K-Ras-PI3K regulates H3K56ac through PCAF to elevate the occurrence and growth of liver cancer[J]. J Cell Physiol, 2020,235(4):3905-3915. DOI: 10.1002/jcp.29284. doi:10.1002/jcp.v235.4pmid:31642074
[14]	Ichise T, Yoshida N, Ichise H. CBP/p300 antagonises EGFR-Ras-Erk signalling and suppresses increased Ras-Erk signaling-induced tumour formation in mice[J]. J Pathol, 2019,249(1):39-51. DOI: 10.1002/path.5279. doi:10.1002/path.5279pmid:30953353
[15]	McHugh A, Fernandes K, South AP, et al. Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity[J]. Oncotarget, 2018,9(29):20265-20281. DOI: 10.18632/oncotarget.24750. doi:10.18632/oncotarget.24750pmid:29755650
[16]	McHugh A, Fernandes K, Chinner N, et al. The identification of potential therapeutic targets for cutaneous squamous cell carcinoma[J]. J Invest Dermatol, 2020,140(6):1154-1165.e5. DOI: 10.1016/j.jid.2019.09.024. doi:10.1016/j.jid.2019.09.024pmid:31705877
[17]	Xu J, Meng Q, Li X, Yang H, et al. Long noncoding RNA MIR17HG promotes colorectal cancer progression via miR-17-5p[J]. Cancer Res, 2019,79(19):4882-4895. DOI: 10.1158/0008-5472.CAN-18-3880. doi:10.1158/0008-5472.CAN-18-3880pmid:31409641
[18]	Vidovic D, Huynh TT, Konda P, et al. ALDH1A3-regulated long non-coding RNA NRAD1 is a potential novel target for triple-negative breast tumors and cancer stem cells[J]. Cell Death Differ, 2020,27(1):363-378. DOI: 10.1038/s41418-019-0362-1. doi:10.1038/s41418-019-0362-1pmid:31197235
[19]	He K, Li WX, Guan D, et al. Regulatory network reconstruction of five essential microRNAs for survival analysis in breast cancer by integrating miRNA and mRNA expression datasets[J]. Funct Integr Genomics, 2019,19(4):645-658. DOI: 10.1007/s10142-019-00670-7. pmid:30859354
[20]	Gong ZH, Zhou F, Shi C, et al. miRNA-221 promotes cutaneous squamous cell carcinoma progression by targeting PTEN[J]. Cell Mol Biol Lett, 2019,24:9. DOI: 10.1186/s11658-018-0131-z. doi:10.1186/s11658-018-0131-zpmid:30891072
[21]	Sand M, Bechara FG, Sand D, et al. Expression profiles of long noncoding RNAs in cutaneous squamous cell carcinoma[J]. Epigenomics, 2016,8(4):501-518. DOI: 10.2217/epi-2015-0012. doi:10.2217/epi-2015-0012pmid:27067026
[22]	Yu GJ, Sun Y, Zhang DW, et al. Long non-coding RNA HOTAIR functions as a competitive endogenous RNA to regulate PRAF2 expression by sponging miR-326 in cutaneous squamous cell carcinoma[J]. Cancer Cell Int, 2019,19:270. DOI: 10.1186/s12935-019-0992-x. doi:10.1186/s12935-019-0992-xpmid:31649487